Nutriband Inc. (NASDAQ: NTRB) has announced that its Chairman and Co-Founder, Serguei Melnik, is scheduled to present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation will take place on December 3 at 9:30 a.m. Eastern at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida. Investors and guests can attend at a discounted rate by using the code NTRBNOBLECON. A high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days.
This presentation is significant as it provides Nutriband with a platform to discuss its lead product under development: an abuse-deterrent fentanyl patch that incorporates the company's proprietary AVERSA abuse-deterrent technology. The AVERSA technology is designed to be integrated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Fentanyl is a potent synthetic opioid that is a major contributor to the opioid crisis, and an abuse-deterrent formulation could have substantial public health implications.
The conference, NobleCon21, focuses on emerging growth companies and attracts a wide range of investors, analysts, and industry professionals. Nutriband's participation underscores its commitment to advancing its transdermal portfolio and engaging with the investment community. The company is primarily engaged in developing a range of transdermal pharmaceutical products, with the AVERSA-fentanyl patch being the most advanced in its pipeline.
For more information about Nutriband, including the latest news and updates, the company maintains a newsroom at https://nnw.fm/NTRB. Additionally, the full press release regarding the NobleCon21 presentation is available at https://nnw.fm/Bx5x3.
The presentation at NobleCon21 represents a key opportunity for Nutriband to highlight its innovative approach to addressing opioid abuse through transdermal technology. With the opioid crisis continuing to affect communities worldwide, technologies like AVERSA could play a critical role in reducing harm. The company's focus on abuse-deterrent formulations aligns with regulatory priorities and public health needs, making this presentation particularly relevant for investors interested in pharmaceutical innovation and safety.
